US approves Boehringer`s once-a-day inhaler drug
Washington: The Food and Drug Administration (FDA) has approved a new long-acting inhaler drug from Boehringer Ingelheim to treat people with chronic lung disease.
The agency approved Striverdi Respimat for chronic obstructive pulmonary disease, which causes bronchitis and emphysema. The disease, which is most often caused by smoking, is the third leading cause of death in the US, according to the National Institutes of Health.
The FDA approved the drug today based on a study in 3,104 patients which showed improvements in lung function versus placebo.
The drug will carry a bold warning that it is not approved to treat patients with asthma. Striverdi Respimate is part of a family of medications that have been linked to asthma-related deaths.
Download the all new Zee News app for Android and iOS to stay up to date with latest headlines and news stories in Politics, Entertainment, Sports, Technology, Business and much more from India and around the world.
More from India
More from World
More from Sports
More from Entertaiment
- Intolerance issue: Proud to be Indian, won't leave country, says Aamir Khan
- If India was intolerant, then Kiran Rao wouldn't have married Aamir Khan: Baba Ramdev
- Watch: Chicago cop shoots a 17-year-old black man 16 times
- Army camp attacked in J&K's Kupwara; three JeM terrorists, one civilian killed
- Aamir Khan's remarks on intolerance stir controversy; BJP slams, film fraternity split